论文部分内容阅读
探讨应用反义核酸（ＡＳＯＤＮ）替代ＡＴＲＡ治疗急性早幼粒细胞白血病（ＡＰＬ）的可行性。ＮＢ４和ＨＬ－６０细胞的生长、分化及功能通过细胞生长曲线、形态学、细胞表面标志及ＮＢＴ还原试验加以判定，细胞周期应用流式细胞仪进行分析。结果显示：①ＡＳＯＤＮ仅能够抑制ＮＢ４的生长，促进ＮＢ４细胞的分化，具有特异性；②ＡＴＲＡ能够同时影响ＮＢ４和ＨＬ－６０细胞的生长分化；③ＡＳＯＤＮ能够降低ＮＢ４细胞Ｓ期细胞百分比，而ＡＴＲＡ不能；④与ＡＴＲＡ相比，ＡＳＯＤＮ对ＮＢ４细胞ＰＭＬ－ＲＡＲα融合基因的抑制作用强，作用时相早。因此，通过单纯封闭ＰＭＬ－ＲＡＲα基因对ＡＰＬ行使基因治疗是可行的，而将ＰＭＬ－ＲＡＲα基因的封闭和ＲＡＲα基因的激活结合起来也许是基因治疗的最佳方案。
To investigate the feasibility of using ASODN instead of ATRA in the treatment of acute promyelocytic leukemia (APL). The growth, differentiation and function of NB4 and HL-60 cells were determined by cell growth curves, morphology, cell surface markers, and NBT reduction assays, and cell cycle analysis was performed using flow cytometry. The results showed that: 1ASODN can only inhibit the growth of NB4, and promote the differentiation of NB4 cells, and has specificity; 2ATRA can simultaneously affect the growth and differentiation of NB4 and HL-60 cells; 3ASODN can reduce the percentage of S phase cells in NB4 cells, but ATRA can not; 4 Compared with ATRA, ASODN has a strong inhibitory effect on the PML-RARα fusion gene of NB4 cells, and its action phase is early. Therefore, it is feasible to perform gene therapy for APL by simply blocking the PML-RARα gene, and combining the blocking of PML-RARα gene with the activation of RARα gene may be the best solution for gene therapy.